 | • レポートコード：MRC2312MG00647 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の医薬品用中間体CDMO市場規模と予測を収録しています。・世界の医薬品用中間体CDMO市場：売上、2018年-2023年、2024年-2029年 ・世界の医薬品用中間体CDMO市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の医薬品用中間体CDMO市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「低分子CDMO」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 医薬品用中間体CDMOのグローバル主要企業は、Cambrex、 WR Grace、 Esteve Química、 AGC Pharma Chemicals、 Evonik、 CordenPharma、 Otsuka Chemical、 Wavelength、 KBI Biopharma、 Chengda Pharmaceuticals、 Apeloa Pharmaceutical、 Xi'an Manareco New Materials、 Shenzhen Sungening Bio-technology、 Chengdu D-innovation Pharmaceutical、 Huateng Pharmaなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、医薬品用中間体CDMOのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の医薬品用中間体CDMO市場：タイプ別、2018年-2023年、2024年-2029年 世界の医薬品用中間体CDMO市場：タイプ別市場シェア、2022年 ・低分子CDMO、高分子CDMO 世界の医薬品用中間体CDMO市場：用途別、2018年-2023年、2024年-2029年 世界の医薬品用中間体CDMO市場：用途別市場シェア、2022年 ・製薬会社、バイオテクノロジー会社、その他 世界の医薬品用中間体CDMO市場：地域・国別、2018年-2023年、2024年-2029年 世界の医薬品用中間体CDMO市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における医薬品用中間体CDMOのグローバル売上、2018年-2023年 ・主要企業における医薬品用中間体CDMOのグローバル売上シェア、2022年 ・主要企業における医薬品用中間体CDMOのグローバル販売量、2018年-2023年 ・主要企業における医薬品用中間体CDMOのグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Cambrex、 WR Grace、 Esteve Química、 AGC Pharma Chemicals、 Evonik、 CordenPharma、 Otsuka Chemical、 Wavelength、 KBI Biopharma、 Chengda Pharmaceuticals、 Apeloa Pharmaceutical、 Xi'an Manareco New Materials、 Shenzhen Sungening Bio-technology、 Chengdu D-innovation Pharmaceutical、 Huateng Pharma ************************************************************* ・調査・分析レポートの概要 医薬品用中間体CDMO市場の定義 市場セグメント 世界の医薬品用中間体CDMO市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の医薬品用中間体CDMO市場規模 世界の医薬品用中間体CDMO市場規模：2022年 VS 2029年 世界の医薬品用中間体CDMO市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの医薬品用中間体CDMOの売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の医薬品用中間体CDMO製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：低分子CDMO、高分子CDMO 医薬品用中間体CDMOのタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：製薬会社、バイオテクノロジー会社、その他 医薬品用中間体CDMOの用途別グローバル売上・予測 ・地域別市場分析 地域別医薬品用中間体CDMO市場規模 2022年と2029年 地域別医薬品用中間体CDMO売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Cambrex、 WR Grace、 Esteve Química、 AGC Pharma Chemicals、 Evonik、 CordenPharma、 Otsuka Chemical、 Wavelength、 KBI Biopharma、 Chengda Pharmaceuticals、 Apeloa Pharmaceutical、 Xi'an Manareco New Materials、 Shenzhen Sungening Bio-technology、 Chengdu D-innovation Pharmaceutical、 Huateng Pharma ... |
This research report provides a comprehensive analysis of the Pharmaceutical Intermediate CDMO market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Pharmaceutical Intermediate CDMO market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Pharmaceutical Intermediate CDMO, challenges faced by the industry, and potential opportunities for market players.
The global Pharmaceutical Intermediate CDMO market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Pharmaceutical Intermediate CDMO market presents opportunities for various stakeholders, including Pharmaceutical Company, Biotechnology Company. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Pharmaceutical Intermediate CDMO market. Additionally, the growing consumer demand present avenues for market expansion.
The global Pharmaceutical Intermediate CDMO market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Pharmaceutical Intermediate CDMO market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Pharmaceutical Intermediate CDMO market.
Market Overview: The report provides a comprehensive overview of the Pharmaceutical Intermediate CDMO market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Small Molecule Cdmo, Macromolecular Cdmo), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Pharmaceutical Intermediate CDMO market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Pharmaceutical Intermediate CDMO market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Pharmaceutical Intermediate CDMO market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Pharmaceutical Intermediate CDMO market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Pharmaceutical Intermediate CDMO market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Pharmaceutical Intermediate CDMO market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Pharmaceutical Intermediate CDMO, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Pharmaceutical Intermediate CDMO market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Pharmaceutical Intermediate CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Small Molecule Cdmo
Macromolecular Cdmo
Market segment by Application
Pharmaceutical Company
Biotechnology Company
Others
Global Pharmaceutical Intermediate CDMO Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Cambrex
WR Grace
Esteve Química
AGC Pharma Chemicals
Evonik
CordenPharma
Otsuka Chemical
Wavelength
KBI Biopharma
Chengda Pharmaceuticals
Apeloa Pharmaceutical
Xi’an Manareco New Materials
Shenzhen Sungening Bio-technology
Chengdu D-innovation Pharmaceutical
Huateng Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Pharmaceutical Intermediate CDMO, market overview.
Chapter 2: Global Pharmaceutical Intermediate CDMO market size in revenue.
Chapter 3: Detailed analysis of Pharmaceutical Intermediate CDMO company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Pharmaceutical Intermediate CDMO in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Pharmaceutical Intermediate CDMO Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Pharmaceutical Intermediate CDMO Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Pharmaceutical Intermediate CDMO Overall Market Size
2.1 Global Pharmaceutical Intermediate CDMO Market Size: 2022 VS 2029
2.2 Global Pharmaceutical Intermediate CDMO Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Pharmaceutical Intermediate CDMO Players in Global Market
3.2 Top Global Pharmaceutical Intermediate CDMO Companies Ranked by Revenue
3.3 Global Pharmaceutical Intermediate CDMO Revenue by Companies
3.4 Top 3 and Top 5 Pharmaceutical Intermediate CDMO Companies in Global Market, by Revenue in 2022
3.5 Global Companies Pharmaceutical Intermediate CDMO Product Type
3.6 Tier 1, Tier 2 and Tier 3 Pharmaceutical Intermediate CDMO Players in Global Market
3.6.1 List of Global Tier 1 Pharmaceutical Intermediate CDMO Companies
3.6.2 List of Global Tier 2 and Tier 3 Pharmaceutical Intermediate CDMO Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Pharmaceutical Intermediate CDMO Market Size Markets, 2022 & 2029
4.1.2 Small Molecule Cdmo
4.1.3 Macromolecular Cdmo
4.2 By Type – Global Pharmaceutical Intermediate CDMO Revenue & Forecasts
4.2.1 By Type – Global Pharmaceutical Intermediate CDMO Revenue, 2018-2023
4.2.2 By Type – Global Pharmaceutical Intermediate CDMO Revenue, 2024-2029
4.2.3 By Type – Global Pharmaceutical Intermediate CDMO Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Pharmaceutical Intermediate CDMO Market Size, 2022 & 2029
5.1.2 Pharmaceutical Company
5.1.3 Biotechnology Company
5.1.4 Others
5.2 By Application – Global Pharmaceutical Intermediate CDMO Revenue & Forecasts
5.2.1 By Application – Global Pharmaceutical Intermediate CDMO Revenue, 2018-2023
5.2.2 By Application – Global Pharmaceutical Intermediate CDMO Revenue, 2024-2029
5.2.3 By Application – Global Pharmaceutical Intermediate CDMO Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Pharmaceutical Intermediate CDMO Market Size, 2022 & 2029
6.2 By Region – Global Pharmaceutical Intermediate CDMO Revenue & Forecasts
6.2.1 By Region – Global Pharmaceutical Intermediate CDMO Revenue, 2018-2023
6.2.2 By Region – Global Pharmaceutical Intermediate CDMO Revenue, 2024-2029
6.2.3 By Region – Global Pharmaceutical Intermediate CDMO Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Pharmaceutical Intermediate CDMO Revenue, 2018-2029
6.3.2 US Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.3.3 Canada Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.3.4 Mexico Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Pharmaceutical Intermediate CDMO Revenue, 2018-2029
6.4.2 Germany Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.4.3 France Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.4.4 U.K. Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.4.5 Italy Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.4.6 Russia Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.4.7 Nordic Countries Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.4.8 Benelux Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Pharmaceutical Intermediate CDMO Revenue, 2018-2029
6.5.2 China Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.5.3 Japan Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.5.4 South Korea Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.5.5 Southeast Asia Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.5.6 India Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Pharmaceutical Intermediate CDMO Revenue, 2018-2029
6.6.2 Brazil Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.6.3 Argentina Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Pharmaceutical Intermediate CDMO Revenue, 2018-2029
6.7.2 Turkey Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.7.3 Israel Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.7.4 Saudi Arabia Pharmaceutical Intermediate CDMO Market Size, 2018-2029
6.7.5 UAE Pharmaceutical Intermediate CDMO Market Size, 2018-2029
7 Pharmaceutical Intermediate CDMO Companies Profiles
7.1 Cambrex
7.1.1 Cambrex Company Summary
7.1.2 Cambrex Business Overview
7.1.3 Cambrex Pharmaceutical Intermediate CDMO Major Product Offerings
7.1.4 Cambrex Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.1.5 Cambrex Key News & Latest Developments
7.2 WR Grace
7.2.1 WR Grace Company Summary
7.2.2 WR Grace Business Overview
7.2.3 WR Grace Pharmaceutical Intermediate CDMO Major Product Offerings
7.2.4 WR Grace Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.2.5 WR Grace Key News & Latest Developments
7.3 Esteve Química
7.3.1 Esteve Química Company Summary
7.3.2 Esteve Química Business Overview
7.3.3 Esteve Química Pharmaceutical Intermediate CDMO Major Product Offerings
7.3.4 Esteve Química Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.3.5 Esteve Química Key News & Latest Developments
7.4 AGC Pharma Chemicals
7.4.1 AGC Pharma Chemicals Company Summary
7.4.2 AGC Pharma Chemicals Business Overview
7.4.3 AGC Pharma Chemicals Pharmaceutical Intermediate CDMO Major Product Offerings
7.4.4 AGC Pharma Chemicals Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.4.5 AGC Pharma Chemicals Key News & Latest Developments
7.5 Evonik
7.5.1 Evonik Company Summary
7.5.2 Evonik Business Overview
7.5.3 Evonik Pharmaceutical Intermediate CDMO Major Product Offerings
7.5.4 Evonik Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.5.5 Evonik Key News & Latest Developments
7.6 CordenPharma
7.6.1 CordenPharma Company Summary
7.6.2 CordenPharma Business Overview
7.6.3 CordenPharma Pharmaceutical Intermediate CDMO Major Product Offerings
7.6.4 CordenPharma Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.6.5 CordenPharma Key News & Latest Developments
7.7 Otsuka Chemical
7.7.1 Otsuka Chemical Company Summary
7.7.2 Otsuka Chemical Business Overview
7.7.3 Otsuka Chemical Pharmaceutical Intermediate CDMO Major Product Offerings
7.7.4 Otsuka Chemical Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.7.5 Otsuka Chemical Key News & Latest Developments
7.8 Wavelength
7.8.1 Wavelength Company Summary
7.8.2 Wavelength Business Overview
7.8.3 Wavelength Pharmaceutical Intermediate CDMO Major Product Offerings
7.8.4 Wavelength Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.8.5 Wavelength Key News & Latest Developments
7.9 KBI Biopharma
7.9.1 KBI Biopharma Company Summary
7.9.2 KBI Biopharma Business Overview
7.9.3 KBI Biopharma Pharmaceutical Intermediate CDMO Major Product Offerings
7.9.4 KBI Biopharma Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.9.5 KBI Biopharma Key News & Latest Developments
7.10 Chengda Pharmaceuticals
7.10.1 Chengda Pharmaceuticals Company Summary
7.10.2 Chengda Pharmaceuticals Business Overview
7.10.3 Chengda Pharmaceuticals Pharmaceutical Intermediate CDMO Major Product Offerings
7.10.4 Chengda Pharmaceuticals Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.10.5 Chengda Pharmaceuticals Key News & Latest Developments
7.11 Apeloa Pharmaceutical
7.11.1 Apeloa Pharmaceutical Company Summary
7.11.2 Apeloa Pharmaceutical Business Overview
7.11.3 Apeloa Pharmaceutical Pharmaceutical Intermediate CDMO Major Product Offerings
7.11.4 Apeloa Pharmaceutical Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.11.5 Apeloa Pharmaceutical Key News & Latest Developments
7.12 Xi’an Manareco New Materials
7.12.1 Xi’an Manareco New Materials Company Summary
7.12.2 Xi’an Manareco New Materials Business Overview
7.12.3 Xi’an Manareco New Materials Pharmaceutical Intermediate CDMO Major Product Offerings
7.12.4 Xi’an Manareco New Materials Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.12.5 Xi’an Manareco New Materials Key News & Latest Developments
7.13 Shenzhen Sungening Bio-technology
7.13.1 Shenzhen Sungening Bio-technology Company Summary
7.13.2 Shenzhen Sungening Bio-technology Business Overview
7.13.3 Shenzhen Sungening Bio-technology Pharmaceutical Intermediate CDMO Major Product Offerings
7.13.4 Shenzhen Sungening Bio-technology Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.13.5 Shenzhen Sungening Bio-technology Key News & Latest Developments
7.14 Chengdu D-innovation Pharmaceutical
7.14.1 Chengdu D-innovation Pharmaceutical Company Summary
7.14.2 Chengdu D-innovation Pharmaceutical Business Overview
7.14.3 Chengdu D-innovation Pharmaceutical Pharmaceutical Intermediate CDMO Major Product Offerings
7.14.4 Chengdu D-innovation Pharmaceutical Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.14.5 Chengdu D-innovation Pharmaceutical Key News & Latest Developments
7.15 Huateng Pharma
7.15.1 Huateng Pharma Company Summary
7.15.2 Huateng Pharma Business Overview
7.15.3 Huateng Pharma Pharmaceutical Intermediate CDMO Major Product Offerings
7.15.4 Huateng Pharma Pharmaceutical Intermediate CDMO Revenue in Global Market (2018-2023)
7.15.5 Huateng Pharma Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer